Navigation Links
Minnesotans Help Produce As Well As Benefit from Lifesaving Therapies
Date:9/1/2010

ANNAPOLIS, Md., Sept. 1 /PRNewswire/ -- This month, Minnesotans are recognized for their outstanding contributions to lifesaving therapies that treat critically ill individuals and for their donations of the blood component, plasma, that makes the creation of these unique therapies possible. Throughout September, Minnesota Gov. Tim Pawlenty is recognizing "Plasma Protein Therapies Month" in the North Star State, helping to raise awareness for the rare, genetic diseases treated with the therapies and valuing the contributions of voluntary plasma donors in the state.

(Logo: http://photos.prnewswire.com/prnh/20100901/NE58605LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100901/NE58605LOGO)

Plasma protein therapies, which include plasma-derived therapies and recombinant blood clotting factors (a biotechnology product), are used every day to treat people with hemophilia, a blood clotting disorder that causes painful internal bleeding and debilitating joint damage; primary immunodeficiency diseases, which rob a person's ability to fight even common infections; and alpha-1 antitrypsin deficiency, also known as genetic chronic obstructive pulmonary disease (COPD). In addition, a plasma protein therapy, albumin, is used in critical care settings, when treating severe trauma, burns and during major surgery.

Plasma, a biological material that cannot be manufactured, is used to create lifesaving therapies that come solely from committed plasma donors. The state of Minnesota is home to 11 plasma collection centers. As Minnesota celebrates the generosity of its donors and raises awareness for the rare diseases that are treated with the therapies during Plasma Protein Therapies Month, we encourage everyone to donate and to help ensure a higher quality of life for patients across the United States and around the world.

"Always serious and often life-threatening, patients requiring plasma protein therapies suffer from serious diseas
'/>"/>

SOURCE Plasma Protein Therapeutics Association (PPTA)
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Organic Is Answer to Those Seeking Foods Produced Without Antibiotics
2. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
3. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
6. Arrayit to Mass Produce Rapid H1N1 Swine Flu Test Chip
7. Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050
8. Senesco Chooses VGXI to Produce Factor 5A Plasmid
9. Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
10. Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists
11. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013  TechAtlas Group has announced the ... landscape map for the Chronic Kidney Disease (CKD) ... companies with drugs and devices currently on the ... sequelae. (Logo:  http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ... hypertension - renal denervation , diabetic nephropathy ...
(Date:5/17/2013)... 17, 2013 Fuse Science, Inc. (OTCQB: DROP), ( ... is developing new, patent-pending technologies poised to redefine how consumers ... will hold a business update teleconference and webcast for shareholders ... 2013 at 4:30 PM ET. Fuse Science, ... the call and will be joined by Rubin ...
(Date:5/17/2013)... 2013  Sanofi (EURONEXT: SAN and NYSE: SNY ... JAKARTA , examining the selective JAK2 inhibitor SAR302503 ... dose groups. The primary endpoint assessed the proportion of ... data reported in previous trials, the most common adverse ... will be presented at an upcoming medical congress. ...
Breaking Medicine Technology:TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
(Date:5/18/2013)... (May 18, 2013) There are significant cost ... used to diagnose or treat gastrointestinal problems, according ... , A study by New York Presbyterian ... objective testing may substantially reduce the cost and ... GERD is believed to affect nearly 25 percent ...
(Date:5/18/2013)... Today, Zane Benefits, Inc. published ... in Marketplaces . Zane Benefits, which provides comprehensive ... benefits, is the leader in health care reform, ... arrangements . , According to Zane Benefits’ website, ... recently released a much-anticipated statement and Q&A on ...
(Date:5/18/2013)... 2013 After working diligently for months and ... formally announced the integration of the fitment specs for the ... set to stun the automobile market with its extraordinary features ... is marked as the latest entry in the size ... up for the year 2013. , Aptly suiting its ...
(Date:5/18/2013)... Although obesity is associated with an increased risk ... esophageal adenocarcinoma, a type of esophageal cancer, is stronger ... on Cancer.gov, last reviewed in January 2012, overweight ... those of normal and healthy weight to develop this ... cancer is not well understood, it is now thought ...
(Date:5/18/2013)... Houston, TX (PRWEB) May 18, 2013 Show ... many years of various different training systems that is all ... possible has caught the attention of http://ShowAndGoTrainingReview.com ’s ... Go Training is a unique “four phase system” designed ... the minimum amount of time spent working out in the ...
Breaking Medicine News(10 mins):Health News:New research identifies practice changes to improve value and quality of GI procedures 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 3Health News:Show And Go Training: Review Examining Eric Cressy's Workout Program Revealed 2
... polymer, fitted with molecular pincers of carefully tailored structure, ... can be used for fabrication of sensitive and selective ... the near future also in gases. Moreover, the polymer ... for therapeutic purposes. The collaboration of researchers of ...
... tripled in the United States between 1999 and 2006, ... heroin overdoses combined. Hospitalizations and emergency room visits related ... name Oxycontin) and hydrocodone (Vicodin) also increased dramatically in ... the August issue of Health Affairs describes ...
... Goodwin HealthDay Reporter , WEDNESDAY, Aug. 3 ... certain markers in the blood called "autoantibodies" is showing ... blood test correctly detected Alzheimer,s disease in people already ... accuracy, according to the researchers. The test could also ...
... Society of America (GSA) the nation,s largest interdisciplinary organization ... Ferraro, PhD, of Purdue University as the 2011 recipient of ... given to individuals who have not only fostered excellence in ... of their mentoring, and whose inspiration is sought by students ...
... A Mayo Clinic orthopedic surgeon suspects that the nagging ... knees may be different from what men encounter, and ... study to explore the question. The Society for Women,s ... (ISIS) Network on Musculoskeletal Health has awarded a group ...
... Scientists at Cold Spring Harbor Laboratory (CSHL) and five other ... to identify a new potential treatment for acute myeloid leukemia ... 3, the scientists have pinpointed a protein called Brd4 as ... that is currently incurable in 70% of patients. Using a ...
Cached Medicine News:Health News:Polymer's hunt for nicotine 2Health News:Polymer's hunt for nicotine 3Health News:Group Health establishes major initiative to prevent opioid abuse and overdose 2Health News:Group Health establishes major initiative to prevent opioid abuse and overdose 3Health News:Another Blood Test for Alzheimer's Shows Promise 2Health News:Another Blood Test for Alzheimer's Shows Promise 3Health News:Another Blood Test for Alzheimer's Shows Promise 4Health News:Ferraro to receive GSA's 2011 Distinguished Mentorship in Gerontology Award 2Health News:Mayo Clinic examines why knee osteoarthritis afflicts more women than men 2Health News:Unconventional hunt for new cancer targets leads to a powerful drug candidate for leukemia 2Health News:Unconventional hunt for new cancer targets leads to a powerful drug candidate for leukemia 3Health News:Unconventional hunt for new cancer targets leads to a powerful drug candidate for leukemia 4
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
Medicine Products: